Matthew Drake, MD
Pulmonary Disease · Portland, ORNPI 1245487875
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by AstraZeneca at 46.2% of the total. Reporting peaked in 2023 at $48,298 and has fallen 99.8% since, to $117 in 2025. Among pulmonary disease clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $874.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$62K
- Merck$35K
- GSK$27K
- Chiesi USA, Inc.$4K
- Regeneron Healthcare Solutions, Inc.$3K
- Sanofi$2K
- plus $59 from 1 others
What the payments were for
- Consulting fees$69,25551%
- Speaking & faculty fees$47,59535%
- Travel & lodging$15,30511%
- Food & beverage$2,4912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 76 | $62,180 |
| Merck | 28 | $35,306 |
| GSK | 40 | $27,477 |
| Chiesi USA, Inc. | 1 | $4,200 |
| Regeneron Healthcare Solutions, Inc. | 6 | $3,109 |
| Sanofi | 2 | $2,313 |
| Amgen | 1 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$134,645 in reported general payments places this provider in the 95th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Portland
- Stephen YauPortland$984K
- Peter LeePortland$98K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
- David HotchkinPortland$65K
- Jeffrey RobinsonPortland$51K
- Steven SearsPortland$21K
- Melvin MorganrothPortland$14K
- Christina MacrostyPortland$13K
- Bishoy ZakharyPortland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.